Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Tomás Pascual(Breast Cancer Research Foundation), J.M. Ferrero-Cafiero(Solti), Alexios Matikas(Karolinska University Hospital), Rodrigo Sánchez-Bayona(Hospital Universitario 12 De Octubre), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Fernando Salvador(Solti), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Vı́ctor Navarro(Vall d'Hebron Institut de Recerca), Joana Ribeiro(Inserm), Francesco Schettini(Breast Cancer Research Foundation), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Aleix Prat(University of Padua), Andri Papakonstantinou(Karolinska University Hospital)
Cited by 77
Related Papers
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
|Cancer Research|2017|480
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
|Annals of Oncology|2021|294
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271